Figure 4

Usage of TRBV subgroups and TRBJ genes in patient groups. Relative frequency of TRBV subgroups and TRBJ genes usage in total sequences of group I (PML-NAT#1 and PML-NAT#2 at T0 and T1/T2), group II (PML-NAT#1, PML-NAT#2, PML-NAT#3, PML-NAT#4 and PML-ALEM#5 at T3), and group III (MS#1 and MS#2 at T0 and T3). *P < 0.05; **P < 0.01; and ***P < 0.001.